心通口服液联合美托洛尔对冠心病心绞痛患者血管内皮功能、心肌损伤指标和血清MMP-2、MMP-7、MMP-8、MMP-9的影响

摘要 目的：观察心通口服液联合美托洛尔对冠心病心绞痛患者血管内皮功能、心肌损伤指标和血清基质金属蛋白酶（MMP）-2、MMP-7、MMP-8、MMP-9的影响。方法：按照随机数字表法，将我院2021年1月~2022年5月期间收治的72例冠心病心绞痛患者分为对照组（n=36）和研究组（n=36）。在常规治疗的基础上，对照组患者接受美托洛尔治疗，研究组患者接受心通口服液联合美托洛尔治疗。对比两组疗效、不良反应发生率、心功能指标左室射血分数（LVEF）、心输出量（CO）]、临床指标（心绞痛发作次数、每次发作持续时间、含服硝酸异山梨酯片剂量）、血管内皮功能指标一氧化氮（NO）、血管内皮生长因子（VEGF）、6-酮前列素 F1a（6-keto-PGF1a）]、心肌损伤指标心肌肌钙蛋白I（cTnI）、脑钠肽（BNP）、肌酸激酶同工酶（CK-MB）]和血清MMP-2、MMP-7、MMP-8、MMP-9水平。结果：研究组的临床治疗总有效率（94.44%）高于对照组（75.00%）（P<0.05）。治疗2周后，研究组LVEF、CO高于对照组（P<0.05）。治疗2周后，研究组含服硝酸异山梨酯片剂量、心绞痛发作次数少于对照组，每次发作持续时间短于对照组（P<0.05）。治疗2周后，研究组NO、VEGF、6-keto-PGF1a高于对照组（P<0.05）。治疗2周后，研究组血清MMP-2、MMP-7、MMP-8、MMP-9水平低于对照组（P<0.05）。治疗2周后，研究组CK-MB、BNP、cTnI低于对照组（P<0.05）。两组不良反应发生率对比未见明显差异（P>0.05）。结论：心通口服液联合美托洛尔治疗冠心病心绞痛患者，可改善临床症状，改善机体血管内皮功能、心肌损伤指标、心功能和血清MMP-2、MMP-7、MMP-8、MMP-9水平。

Effects of Xintong Oral Liquid Combined with Metoprolol on Vascular Endothelial Function, Myocardial Injury Index and Serum MMP-2, MMP-7, MMP-8 and MMP-9 in Patients with Coronary Heart Disease with Angina Pectoris

ABSTRACT Objective: To observe the effects of Xintong oral liquid combined with metoprolol on vascular endothelial function, myocardial injury index and serum matrix metalloproteinases (MMP) - 2, MMP-7, MMP-8 and MMP-9 in patients with coronary heart disease with angina pectoris. Methods: According to the random number table method, 72 patients with coronary heart disease with angina pectoris who were admitted to our hospital from January 2021 to May 2022 were divided into control group (n=36) and study group (n=36). On the basis of conventional treatment, patients in the control group received metoprolol treatment, and patients in the study group received Xintong oral liquid combined with metoprolol treatment. The curative effect, adverse reaction rate, cardiac function indicators left ventricular ejection fraction (LVEF) and cardiac output (CO)], clinical indicators (number of angina attacks, duration of each attack, dose of isosorbide nitrate tablets), endothelial function indicators nitric oxide (NO) and vascular endothelial growth factor (VEGF), 6-ketone front row F1a (6-keto-PGF1a)], myocardial injury indicators cardiac troponin I (cTnI), brain natriuretic peptide (BNP), creatine kinase isoenzyme (CK-MB)] and serum MMP-2, MMP-7, MMP-8, MMP-9 levels of two groups were compared. Results: The total effective rate of the study group (94.44%) was higher than (75.00%) of the control group (P<0.05). 2 weeks after treatment, LVEF and CO of the study group were higher than those of the control group (P<0.05). 2 weeks after treatment, the dose of isosorbide nitrate tablets, number of angina attacks of the study group were less than those of the control group, and the duration of each attack was shorter than that of the control group (P<0.05). 2 weeks after treatment, the NO, VEGF and 6-keto-PGF1a of the study group were higher than those of the control group (P<0.05). 2 weeks after treatment, the serum MMP-2, MMP-7, MMP-8 and MMP-9 levels of the study group were lower than those of the control group (P<0.05). 2 weeks after treatment, CK-MB, BNP and cTnI of the study group were lower than those of the control group (P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05). Conclusion: Xintong oral liquid combined with metoprolol in the treatment of patients with coronary heart disease with angina pectoris can improve clinical symptoms, vascular endothelial function, myocardial injury indicators, cardiac function and serum MMP-2, MMP-7, MMP-8 and MMP-9 levels.